Black adults develop heart failure at 39 on average, 20 years before white peers

In the CARDIA cohort, which followed 5,115 Black and white adults aged 18 to 30 for two decades, 75 percent of the Black participants who developed heart failure had hypertension by age 40, compared with 12 percent of those who did not develop the disease. The mean age at heart failure onset in that cohort was 39 years, plus or minus 6. The disease those young adults presented with was not primarily ischemic. It was hypertensive heart disease: years of uncontrolled blood pressure remodeling the left ventricle into a thicker, stiffer chamber that eventually fails.

The Multi-Ethnic Study of Atherosclerosis (MESA) puts the incidence gap in numbers that carry across a general adult population. Over four years of follow-up, African American participants developed congestive heart failure at 4.6 per 1,000 person-years, versus 2.4 per 1,000 person-years in white participants. When the MESA authors adjusted for hypertension and diabetes, the racial difference lost statistical significance. That is the finding to hold onto. The disparity is not written into the biology of race. It is written into who gets diagnosed early, who gets their blood pressure to goal, and who does not.

Chronic high blood pressure forces the left ventricle to pump against elevated afterload. The muscle compensates by hypertrophying, meaning the walls thicken. A thicker wall relaxes poorly between beats. Filling pressures rise. Over years, that pattern produces heart failure with preserved ejection fraction (HFpEF), a form of heart failure in which the heart still squeezes adequately but cannot fill properly. HFpEF is harder to treat than heart failure with reduced ejection fraction (HFrEF), and the 2022 AHA/ACC/HFSA Heart Failure Guideline gives HFpEF a narrower menu of disease-modifying therapies than HFrEF.

Black patients carry a larger share of the HFpEF burden in U.S. registries, and hypertensive heart disease is the pathway that puts them there. A Black patient who reached age 35 with uncontrolled blood pressure has likely already begun accumulating left ventricular mass that no medication will fully reverse. The clinical implication is direct: blood pressure control in the third and fourth decades of life is not a wellness goal. It is cardiac structural prevention.

The African-American Heart Failure Trial (A-HeFT) enrolled 1,050 self-identified Black patients with NYHA class III or IV heart failure on standard therapy and randomized them to placebo or fixed-dose isosorbide dinitrate plus hydralazine. The trial was stopped early. In the treatment arm, all-cause mortality dropped 43 percent, from 10.2 percent to 6.2 percent, and first heart failure hospitalizations fell 33 percent. The two drugs are generic and decades old. The hypothesis was that Black patients with advanced HFrEF have a nitric oxide deficit that standard renin-angiotensin therapy does not address, and that nitrate plus hydralazine corrects it.

A-HeFT remains the only large randomized trial of a heart failure therapy designed around a self-identified racial group. The 2022 AHA/ACC/HFSA Heart Failure Guideline carries the A-HeFT result forward as a Class I recommendation: the combination of hydralazine and isosorbide dinitrate is recommended in self-identified African American patients with NYHA class III to IV HFrEF who remain symptomatic on optimal therapy with a renin-angiotensin system inhibitor, beta-blocker, and mineralocorticoid receptor antagonist. Yet real-world prescribing data show this combination is underused in exactly the patients the trial enrolled to help. That is a gap between evidence and practice that patients themselves can close at the clinic visit.

HFpEF now accounts for about half of all heart failure in the United States, per the 2024 AHA Heart Disease and Stroke Statistics Update. Because hypertensive heart disease drives HFpEF more often than it drives HFrEF, and because Black adults carry a higher prevalence and earlier onset of hypertension, the HFpEF patient population skews toward Black patients in many U.S. registries. The disease-modifying therapies that work for HFrEF, including angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists, have a narrower evidence base in HFpEF. The 2022 guideline does give a Class IIa recommendation to SGLT2 inhibitors in HFpEF, and that recommendation applies regardless of race.

A patient whose diagnosis is HFpEF should ask whether an SGLT2 inhibitor has been offered or explained, whether blood pressure is at target (under 130/80 in most heart failure guidelines), and whether sleep apnea has been evaluated. Obstructive sleep apnea is common, underdiagnosed, and a potent driver of diastolic dysfunction.

The questions below are the ones I want patients to bring to the clinic. They are specific, and a good cardiologist will welcome specificity.

1. What is my ejection fraction, and is my heart failure HFrEF or HFpEF? A patient who does not know the answer to this cannot follow the rest of their own care. If the last echocardiogram is older than a year, ask when the next one is scheduled.

2. If I have HFrEF and I am still symptomatic on a beta-blocker, an ACE inhibitor or ARB or ARNI, and a mineralocorticoid receptor antagonist, am I a candidate for isosorbide dinitrate and hydralazine? The 2022 guideline gives this a Class I recommendation for self-identified African American patients in NYHA class III to IV on optimal therapy.

3. Am I on an SGLT2 inhibitor? The 2022 guideline supports SGLT2 inhibitors across HFrEF and HFpEF, and the evidence base includes sizeable Black enrollment. If cost is a barrier, ask about manufacturer assistance programs.

4. What is my blood pressure target, and what is my average reading at home? Home readings matter more than a single clinic reading. If you do not have a validated cuff, ask your clinic to recommend one and check it against the office cuff at your next visit.

5. Have I been evaluated for sleep apnea? Snoring, witnessed pauses, and daytime fatigue in a patient with hypertension and heart failure earn a sleep study.

6. What is the plan if I gain more than three pounds in a week or my ankles swell? A written action plan reduces hospitalization risk. If your clinic does not have one on paper for you, request it.

The CARDIA and MESA findings together describe a preventable disease. Black adults are not developing heart failure at 39 because of something inscribed in their DNA. They are developing it because their blood pressure was 150/95 at 28 and nobody escalated therapy, or because their clinic never asked about home readings, or because the cost of a third antihypertensive was out of reach. Each of those is fixable at the appointment level. Ask your cardiologist whether hydralazine and isosorbide dinitrate belong in your regimen if you have HFrEF, request a written action plan for weight gain and swelling, and bring your home blood pressure log to every visit.